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Abstract: Experimental studies have demonstrated that not only dopaminergic signaling but also glutamatergic/NMDA 
receptor signaling play indispensable roles in the development of methamphetamine psychosis. Our recent genetic studies 
provided evidence that genetic variants of glutamate-related genes such as DTNBP1, GLYT1, and G72, which are involved 
in glutamate release and regulation of co-agonists for NMDA receptors, conferred susceptibility to methamphetamine 
psychosis. Serine racemase converts l-serine to d-serine, which is an endogenous co-agonist for NMDA receptors. Three 
single nucleotide polymorphisms (SNPs) in the promoter region of the serine racemase gene (SRR), rs224770, rs3760229, 
and rs408067, were proven to affect the transcription activity of SRR. Therefore, we examined these SNPs in 225 patients 
with methamphetamine psychosis and 291 age- and sex-matched controls. There was no significant association between 
methamphetamine psychosis and any SNP examined or between the disorder and haplotypes comprising the three SNPs. 
However, rs408067 was significantly associated with the prognosis for methamphetamine psychosis and multi-substance 
abuse status. The patients with C-positive genotypes (CC or CG) of rs408067 showed better prognosis of psychosis after 
therapy and less abuse of multiple substances than the patients with GG genotypes. Because the C allele of rs408067  
reduces the expression of SRR, a lower d-serine level or reduced NMDA receptor activation may affect the prognosis of 
methamphetamine psychosis and multiple substance abuse. Our sample size is, however, not large enough to eliminate the 
possibility of a type I error, our findings must be confirmed by replicate studies with larger samples.  
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INTRODUCTION 
  Methamphetamine is widely abused around the world [1, 
2]. In Japan, it has been the most popular illegal abused sub-
stance since World War II, and its use produces serious so-
cial problems [3, 4]. Development of novel or innovative 
medicines that are more efficient for treatment of metham-
phetamine use disorders is necessary. Methamphetamine has 
a strong pyschostimulant effect on the CNS, and elucidation 
of the neuronal mechanisms underlying methamphetamine-
induced psychological dependence and psychosis is consid-
ered a top priority. Many experimental studies using a be-
havioral sensitization model, an animal model of metham-
phetamine dependence and psychosis, have revealed that the 
dopamine system in the brain plays central and indispensable 
roles in the induction and expression of methamphetamine 
use disorders [5]. These findings seem reasonable because 
methamphetamine is an indirect dopamine agonist. In addi-
tion, animal studies have also revealed that glutamate and its 
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N-methyl-D-aspartate (NMDA) receptors play important 
roles in methamphetamine use disorders. Thus, metham-
phetamine administration enhanced glutamate release in the 
rat accumbens and ventral tegmentum area (VTA) [6, 7]. 
Repeated amphetamine administration results in enhanced 
neuronal responsiveness to locally applied glutamate in the 
VTA [8, 9] and frontal cortex [10]. Repeated methampheta-
mine administration induces behavioral sensitization, which 
was blocked by co-administration of MK-801 (dizocilpine) 
or CPP (D, L-3 [(+/-)-2-carboxypiperazin-4-yl]-propyl-1-
phosphonic acid), an NMDA-receptor antagonist by systemic 
administration or microinjection into the VTA [11-14]; fur-
ther, infusion of iGluR antagonists into the accumbens re-
duced the motor stimulant effects of amphetamine [15]. Re-
ductions in glutamate transmission by administration of the 
glutamate-release inhibitor riluzole [16], the glutamate trans-
porter activator MS-153 [17], infusion of an AMPA (-
amino-3-hydroxy-5-methyl-4-isoazole-proprionic acid)/KA 
(kainite) antagonist into the accumbens [18], and virally me-
diated overexpression of EAAT2 (a glial high affinity gluta-
mate transporter, SLC1A2) in the accumbens [19] all have 
been shown to attenuate the development of amphetamine 
conditioned place preference. Mice deficient in GluRepsi-
lon1, which is a human ortholog of the NR2A subunit of the 170    Current Neuropharmacology, 2011, Vol. 9, No. 1  Yokobayashi et al. 
NMDA receptor, showed attenuation of acute metham-
phetamine-induced hyperlocomotion and low dose metham-
phetamine-induced sensitization [20]. These experimental 
findings indicate that enhanced glutamate transmission via 
NMDA and/or AMPA receptors due to methamphetamine 
administration is essential for induction of sensitization   
and conditioning to the drug [5]. Therefore, it is possible   
that genomic variants of genes encoding molecules involved 
in glutamate signaling may affect individual susceptibility   
to methamphetamine dependence and psychosis. Based on 
this hypothesis, we previously analyzed the genetic associa-
tions of several genes related to glutamate signaling, such  
as  DTNBP1,  GLYT1, and G72, and found that all these   
genes were significantly associated with methamphetamine 
use disorders [21-23]. Serine racemase is an enzyme that 
converts l-serine to d-serine and increases the level of d-
serine, which is a co-agonist for the NMDA receptor and 
regulates activity of NMDA receptors in the brain [24, 25]. 
Therefore, we investigated a possible association between 
the serine racemase gene (SRR) and methamphetamine   
psychosis. 
MATERIALS AND METHODS 
Subjects 
  The subjects comprised 225 patients with methampheta-
mine psychosis (181 male and 44 female; mean age ± SD, 
37.5 ± 11.9) and 274 age-, gender-, and geographical-origin 
matched healthy controls (217 male and 57 female; mean age 
± SD, 37.6 ± 13.1). All subjects were unrelated Japanese 
born and living in relatively restricted areas of Japan. All 
patients were out- or inpatients in psychiatric hospitals of   
the Japanese Genetics Initiative for Drug Abuse (JGIDA). 
Consensus diagnoses of the patients were made by two 
trained psychiatrists according to ICD-10 criteria on the   
basis of unstructured interviews and medical records. The 
patients suffered from F15.5 (methamphetamine psychosis) 
and also F15.2 (methamphetamine dependence). The con-
trols had no individual or family history of drug dependence 
or major psychotic disorders such as schizophrenia or bipolar 
disorder. This study was approved by the ethics committee 
of each JGIDA institution. After a complete description   
of the study to the subjects, written informed consent was 
obtained. 
Clinical Phenotypes 
  The patients with methamphetamine psychosis were di-
vided into subgroups according to the following clinical 
characteristics: age at first consumption of methampheta-
mine (younger or older than 20 years), latency to the onset of 
psychotic symptoms after the first consumption (less than or 
more than 3 years), prognosis of methamphetamine psycho-
sis after therapy (transient type: psychotic symptoms disap-
peared within 1 month after discontinuance of metham-
phetamine use and treatment with an antipsychotic, or pro-
longed type: psychotic symptoms lasted more than 1 month 
even after discontinuance of methamphetamine use and 
treatment with an antipsychotic), spontaneous relapse to a 
psychotic state, and the presence or absence of multiple-
substance abuse. Detailed information on the clinical sub-
groups of methamphetamine dependence and psychosis was 
reported elsewhere [22, 26]. 
Genotyping 
  Peripheral blood was obtained from the subjects, and 
genomic DNA was extracted from peripheral leukocytes 
using the standard method. Based on our previous study of 
schizophrenia, three SNPs in the promoter region, rs224770, 
rs3760229, and rs408067, were analyzed. The first two SNPs 
were genotyped using TaqMan
®-based techniques (Applied 
Biosystems 7300/7500 Real Time PCR System, Applied 
Biosystems Japan Ltd., Tokyo, Japan) with TaqMan probes 
(assay ID C_1027003_10 for rs224770 and C_1625595_10 
for rs3760229). The polymerase chain reaction was carried 
out in a total volume of 7 μL containing 3.2 μL TaqMan
® 
2Universal PCR Master Mix, 0.32 μLTaqMan
® probe, and 
20 ng of DNA. The amplification protocol was denaturation 
at 95°C for 10 min, followed by 40 cycles of denaturation at 
92°C for 15 sec, and annealing and extension at 60°C for 1 
min. Rs408067 was genotyped by the restriction enzyme 
fragment length polymorphism method. PCR was carried out 
in a total volume of 15 ml with 10% dimethyl sulfoxide and 
0.75 units of Taq DNA polymerase in the reaction mixture 
with mismatch probes (forward: 5' CCG GCC GCA CCT 
CTG CGC ACG CGC GGC 3', reverse: 5' CCC CCT GCC 
GCC CTC CCT TTC CGA ACG 3'). Initial denaturation was 
performed for 5 min at 95°C, then 35 cycles of 30 sec of 
denaturing at 95°C, 30 sec of annealing at 68°C, and 30 sec 
of extension at 72°C were performed, followed by a final 
extension at 72°C for 5 min. The PCR products were then 
analyzed on 4.5% agarose gels after digestion with EheI. 
Statistical Analysis 
  Deviation of the genotypes from Hardy-Weinberg equi-
librium was tested using a chi-square goodness-of-fit test. 
The statistical significance of the difference was assessed by 
a chi-square test (genotype comparison) or log likelihood 
ratio test (allele comparison) at a significance level of 0.05. 
The pairwise linkage disequilibrium (LD) and haplotype 
frequencies were estimated by the EH algorithm using the 
SNPalyze program (Dynacom Co., Mobara, Chiba, Japan). 
RESULTS 
  Genotype distributions and allele frequencies of the three 
SNPs of the SRR gene of the patients with methamphetamine 
psychosis and control subjects are shown in Table 1. The 
genotype distributions of the control subjects did not deviate 
from Hardy-Weinberg equilibrium at any of the three SNPs 
(rs224770,  
2=0.86, P=0.35; rs3760229, 
2=0.11, P=0.74; 
rs408067, 
2=0.48, P=0.49). In the single marker analysis, 
no SNP showed a significant difference between patients and 
control subjects in the frequency distribution of the genotype 
(rs224770,  
2=1.23, P=0.54; rs3760229, 
2=2.51, P=0.29; 
rs408067,  
2=1.21, P=0.55) or allele (rs224770, 
2=0.73, 
P=0.39; rs3760229, 
2=0.026, P=0.87; rs408067, 
2=0.022, 
P=0.88). 
 Table  2 shows the results of the pairwise linkage dise-
quilibrium (LD) among the three SNPs of the SRR gene us-
ing the D’ and r
2 values as an index. The D’ and r
2 between 
each pair of SNPs were above 0.7 and 0.3, respectively, 
which indicated strong LD between the SNPs. Accordingly, 
the three SNPs are located on the same LD block. The LD 
structure found in the present study is consistent with our SRR Gene and Methamphetamine Psychosis  Current Neuropharmacology, 2011, Vol. 9, No. 1    171 
previous study of schizophrenia [27]. Then, we analyzed 
three marker haplotypes consisting of rs224770, rs3760229, 
and rs408067 (Table 3). Five haplotypes were found, and the 
G-T-G haplotype was the major one. There was no signifi-
cant difference in estimated frequencies of haplotypes be-
tween the patients with methamphetamine psychosis and 
controls (global permutation p value = 0.068). 
  Effects of the SNPs on several clinical phenotypes, age at 
first abuse of methamphetamine, latency of psychosis from 
the first abuse, prognosis of psychotic symptoms after ther-
apy, complication of spontaneous relapse of psychosis and 
multi-substance abuse status, were analyzed. Allelic and 
genotypic distributions of rs224770 and rs3760229 were not 
associated with these clinical phenotypes (Table 4A and 4B); 
Table 1.  Association between the SRR Gene and Methamphetamine Psychosis 
Rs 2224770 
Genotype Allele    Group N 
G/G (%)  G/A (%)  A/A (%)  p value  G (%)  A (%)  p value 
Control  291  169 (58.1)  101 (34.7)  21 (7.2)    439 (75.4)  143 (24.6)   
METH   221  118 (53.4)  87 (39.4)  16 (7.2)  0.54  323 (73.1)  119 (26.9)  0.39 
Rs 3760229 
Genotype Allele    Group N 
T/T (%)  T/C (%)  C/C (%)  p value  T (%)  C (%)  p value 
Control  292  94 (32.2)  140 (47.9)  58 (19.9)    328 (56.2)  256 (43.8)   
METH   225  66 (29.3)  123 (54.7)  36 (16.0)  0.29  255 (56.7)  195 (43.3)  0.87 
Rs 408067 
Genotype Allele    Group N 
G/G (%)  G/C (%)  C/C %)  p value  G (%)  C (%)  p value 
Control  291  169 (58.1)  102 (35.1)  20 (6.9)    440 (75.6)  142 (24.4)   
METH   225  128 (56.9)  86 (38.2)  11 (4.9)  0.55  342 (76.0)  108 (24.0)  0.88 
Table 2.  Linkage Disequilibrium Among the Three SNPs of the SRR Gene 
 rs2224770  rs3760229  rs408067   
rs2224770   0.4142  0.9082  r
2 
rs3760229 1    0.3631   
rs408067 0.953  0.9374     
 D'      
 
Table 3.  Association of Haplotypes of the SRR Gene with Methamphetamine Psychosis 
Haplotype    Control   Patients  
rs2224770 rs3760229  rs408067  N=580  N=440 
G T G  0.552  0.554 
A C C  0.237  0.233 
G C G  0.194  0.167 
A C G  0.009  0.032 
G T C  0.007  0.009 
Global permutation p  =0.068. 172    Current Neuropharmacology, 2011, Vol. 9, No. 1  Yokobayashi et al. 
Table 4A-C.  Association of Subgroups with Methamphetamine Psychosis According to Clinical Phenotype 
4A 
rs2224770  Genotype  Allele  
Subgroup  N G/G (%) G/A (%) A/A (%) p value G (%) A (%) p value
Age at First Use
 20y< 118 62(52.5) 47(39.8) 9(7.6)  171(72.5) 65(27.5) 
 20y>= 100 54(54.0) 39(39.0) 7(7.0) 0.98  147(73.5) 53(26.5) 0.82 
Latency of Psychosis 
 3y<  101  52(51.5)  40(39.6)  9(8.9)    144(71.3)  58(28.7)   
 3y>=  92  53(57.6)  35(38.0)  4(4.3)  0.40  141(76.6)  43(23.4)  0.23 
Prognosis of Psychosis 
 Transient  112  53(47.3)  50(44.6)  9(8.0)    156(69.6)  68(30.3)   
 Prolonged  90  55(61.1)  30(33.3)  5(5.6)  0.14  140(30.4)  40(22.2)  0.066 
Spontaneous Relapse 
 No  116  68(58.6)  41(35.3)  7(6.0)    177(76.3)  55(23.7)   
 Yes  81  50(61.7)  26(32.1)  5(6.2)  0.89  126(77.8)  36(22.2)  0.81 
Multi-substance abuse 
 None or mild  137  67(50.8)  52(39.4)  13(9.8)    186(70.5)  78(29.5)   
 Heavy  82  47(57.3)  32(39.0)  3(3.7)  0.22  126(76.8)  38(23.2)  0.15 
 
4B 
rs3760229   Genotype    Allele     
Subgroup   N  T/T (%)  T/C (%)  C/C (%)  p value  T (%)  C (%)  p value 
Age at First Use 
 20y<  119  34(28.6)  67(56.3)  18(15.1)    135(56.7)  103(43.2)   
 20y>=  103  31(30.1)  54(52.4)  18(17.5)  0.91  116(56.3)  90(43.7)  0.88 
Latency of Psychosis 
 3y<  102  32(31.4)  53(52.0)  17(16.7)    117(57.4)  87(42.6)   
 3y>=  95  28(29.5)  55(57.9)  12(12.6)  0.63  111(58.4)  79(41.6)  0.83 
Prognosis of Psychosis 
 Transient  114  29(25.4)  68(59.6)  17(14.9)    126(55.3)  102(44.7)   
 Prolonged  92  32(34.8)  46(50.0)  14(15.2)  0.31  110(59.8)  74(40.2)  0.36 
Spontaneous Relapse 
 No  120  30(25.0)  69(57.5)  21(17.5)    129(53.8)  111(46.2)   
 Yes  94  31(33.0)  51(54.3)  12(12.8)  0.36  113(60.1)  75(39.9)  0.20 
Multi-substance abuse 
 None or mild  135  37(27.4)  71(52.6)  27(20.0)    145(53.7)  125(46.3)   
 Heavy  83  26(31.1)  49(59.0)  8(9.6)  0.13  101(60.8)  65(39.2)  0.14 
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Table 4. contd…. 
4C 
rs408067   Genotype    Allele     
Subgroup   N  G/G (%)  G/C (%)  C/C %)  p value  G (%)  C (%)  p value 
Age at First Use                 
 20y<  119  67(56.3)  45(37.8)  7(5.9)    179(75.2)  59(24.8)   
 20y>=  103  59(57.3)  40(38.8)  4(3.9)  0.95  158(76.7)  48(23.3)  0.85 
Latency of Psychosis                 
 3y<  103  58(56.3)  40(38.8)  5(4.9)    156(75.7)  50(24.3)   
 3y>=  94  56(59.6)  36(38.3)  2(2.1)  0.57  148(78.7)  40(21.3)  0.48 
Prognosis of Psychosis                 
 Transient  114  58(50.9)  52(45.6)  4(3.5)    168(73.7)  60(26.3)   
 Prolonged  92  60(65.2)  27(29.3)  5(5.4)  0.056  147(79.9)  37(20.1)  0.14 
Spontaneous Relapse          (0.039)       
 No  120  65(54.2)  47(39.2)  8(6.7)    177(73.8)  63(26.2)   
 Yes  94  56(59.6)  36(38.3)  2(2.1)  0.27  148(78.7)  40(21.3)  0.23 
Multi-substance abuse                 
 None or mild  135  71(52.6)  54(40.0)  10(7.4)    196(72.6)  74(27.4)   
 Heavy  83  53(63.9)  29(34.9)  1(1.2)  0.067  135(81.3)  31(18.7)  0.038 
                                                                                                                                                                  (0.029) 
P values in parentheses indicate those between GG vs C-positive genotypes (GC and CC). 
 
however, rs408067 was significantly associated with a prog-
nosis for methamphetamine psychosis and multi-substance 
abuse status (Table 4C). The patients with C-positive geno-
types (CC or CG) of rs408067 showed the transient type of 
psychosis significantly more frequently after standard ther-
apy with antipsychotics than the patients with the GG geno-
type (p=0.039). This indicated that C-positive genotypes of 
rs408067 may have a better response to antipsychotic treat-
ment and better prognosis of methamphetamine psychosis. 
The patients with the C allele or C-positive genotypes of 
rs408067 also showed significantly less heavy multi-
substance abuse than those with the G allele or GG genotype 
(p=0.036 and 0.029, respectively). They abuse fewer illegal 
substances other than methamphetamine, such as morphine, 
cocaine, or cannabis. 
DISCUSSION 
  The present study revealed that the SRR gene did not 
affect susceptibility to methamphetamine use disorders, but 
it was associated with several clinical phenotypes of meth-
amphetamine dependence and psychosis. Carriers of the C 
allele of rs408067 showed the less prolonged type of meth-
amphetamine psychosis compared with non-carriers, indicat-
ing a better prognosis after therapy with antipsychotics and 
less multi-substance abuse of illegal drugs other than meth-
amphetamine. Our previous study [27] found that rs408067, 
which is located in the promoter region of the SRR gene, 
may be functional because  an  in vitro luciferase assay 
showed that the C allele had 60% lower promoter activity 
than the G allele did. Therefore, having the C allele of 
rs408067 may produce a decrease in the SRR level and d-
serine conversion, and a decreased level of d-serine, a co-
agonist for NMDA receptors, may result in reduced activity 
of NMDA receptors. Therefore, reduced NMDA receptor 
signaling due to possession of the C allele of rs408067 of the 
SRR gene may be a protective factor against a worse prog-
nosis of methamphetamine psychosis and heavy multi-
substance abuse behaviors. 
  A set of molecules are involved in the regulation of glu-
tamate and NMDA receptor signaling. One of those is dys-
bindin, which is encoded by the DTNBP1 gene. Dysbindin 
was shown to be involved in glutamate release from synaptic 
terminals [28]. Recently, we found that the polymorphisms 
of P1635 (rs3213207) and SNPA (rs2619538) and the three-
locus haplotype of P1655 (rs2619539)-P1635-SNPA of the 
DTNBP1 gene  showed significant associations with meth-
amphetamine psychosis [22]. The P1635 polymorphism of 
DTNBP1 was also associated with a worse prognosis for 
methamphetamine psychosis. We also reported that two 
genes involved in regulation of d-serine were associated with 
methamphetamine psychosis [21, 23]. They were the GLYT1 
and G72 genes. GLYT1 encodes glycine transporter type 1, 
which locates in glia close to NMDA receptors and reuptakes 
glycine and d-serine; both are allosteric co-agonists of 174    Current Neuropharmacology, 2011, Vol. 9, No. 1  Yokobayashi et al. 
NMDA receptors. GLYT1 was significantly associated with 
methamphetamine use disorders. G72 encodes an activator 
of d-amino acid oxidase [29], which metabolizes d-serine by 
oxidation. Two haplotypes of the G72 gene in the 5’ and 3’ 
regions were significantly associated with methamphetamine 
psychosis [21]. Thus, our previous and present findings con-
sistently indicate that genetic variants that may affect neural 
signaling of glutamate and NMDA receptors affect suscepti-
bility to methamphetamine-use disorders including psychosis 
and associated clinical characteristics. 
  The sample size in the present study was not too small, 
but it was not large enough to exclude the possibility of a 
type I error. Therefore, our findings must be replicated in an 
independent larger sample and other populations. 
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